Intravesical mitomycin C for superficial transitional cell carcinoma.
Intravesical instillation of mitomycin C after a transurethral resection of a bladder tumor constitutes a standard treatment modality in the management of superficial transitional cell carcinoma in the urinary bladder. An immediate instillation of mitomycin C after transurethral resection has been shown to reduce the recurrence rate of superficial transitional cell carcinoma. Intravesical mitomycin C is generally considered to be a safe treatment option, but the past few years have seen the publication of a number of case reports on severe complications following mitomycin C instillation. This article reports on the mode of action, as well as the intravesical effects and current indications for mitomycin C instillation. This review will summarize the oncological benefits of mitomycin C in comparison with other intravesical treatments, such as bacillus Calmette-Guérin, and elucidate the incidence and types of possible complications associated with intravesical mitomycin C chemotherapy.
Bolenz
Christian
C
Department of Urology, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. christian.bolenz@uro.ma.uni-heidelberg.de
Cao
Yanwei
Y
Arancibia
Mario Fernández
MF
Trojan
Lutz
L
Alken
Peter
P
Michel
Maurice Stephan
MS
D000283:Administration, Intravesical; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000601:surgery*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D016685:Mitomycin / Q000009:adverse effects / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D012008:Recurrence; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery*
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin